Logo image of KNE.CA

KANE BIOTECH INC (KNE.CA) Stock Fundamental Analysis

TSX-V:KNE - TSX Venture Exchange - CA4838092084 - Common Stock - Currency: CAD

0.08  0 (0%)

Fundamental Rating

2

Taking everything into account, KNE scores 2 out of 10 in our fundamental rating. KNE was compared to 21 industry peers in the Biotechnology industry. KNE has a bad profitability rating. Also its financial health evaluation is rather negative. KNE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year KNE was profitable.
KNE had a negative operating cash flow in the past year.
KNE had negative earnings in each of the past 5 years.
KNE had a negative operating cash flow in each of the past 5 years.
KNE.CA Yearly Net Income VS EBIT VS OCF VS FCFKNE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M -5M

1.2 Ratios

KNE's Return On Assets of 56.72% is amongst the best of the industry. KNE outperforms 95.24% of its industry peers.
Industry RankSector Rank
ROA 56.72%
ROE N/A
ROIC N/A
ROA(3y)-77.63%
ROA(5y)-68.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KNE.CA Yearly ROA, ROE, ROICKNE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10K 20K 30K 40K 50K

1.3 Margins

The Profit Margin of KNE (105.28%) is better than 100.00% of its industry peers.
KNE has a better Gross Margin (50.80%) than 85.71% of its industry peers.
KNE's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 105.28%
GM 50.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y23.23%
GM growth 5Y36.67%
KNE.CA Yearly Profit, Operating, Gross MarginsKNE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

KNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KNE has been increased compared to 1 year ago.
The number of shares outstanding for KNE has been increased compared to 5 years ago.
KNE has a worse debt/assets ratio than last year.
KNE.CA Yearly Shares OutstandingKNE.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
KNE.CA Yearly Total Debt VS Total AssetsKNE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -15.23, we must say that KNE is in the distress zone and has some risk of bankruptcy.
KNE has a Altman-Z score of -15.23. This is comparable to the rest of the industry: KNE outperforms 57.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.23
ROIC/WACCN/A
WACC7.83%
KNE.CA Yearly LT Debt VS Equity VS FCFKNE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

A Current Ratio of 0.80 indicates that KNE may have some problems paying its short term obligations.
With a Current ratio value of 0.80, KNE perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
A Quick Ratio of 0.55 indicates that KNE may have some problems paying its short term obligations.
The Quick ratio of KNE (0.55) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.55
KNE.CA Yearly Current Assets VS Current LiabilitesKNE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

KNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 122.51%, which is quite impressive.
KNE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.34%.
The Revenue for KNE have been decreasing by -20.25% on average. This is quite bad
EPS 1Y (TTM)122.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.21%
Revenue 1Y (TTM)-23.34%
Revenue growth 3Y-51.93%
Revenue growth 5Y-20.25%
Sales Q2Q%78.67%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNE.CA Yearly Revenue VS EstimatesKNE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 8.00, the valuation of KNE can be described as reasonable.
Based on the Price/Earnings ratio, KNE is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of KNE to the average of the S&P500 Index (27.75), we can say KNE is valued rather cheaply.
Industry RankSector Rank
PE 8
Fwd PE N/A
KNE.CA Price Earnings VS Forward Price EarningsKNE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNE.CA Per share dataKNE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KANE BIOTECH INC

TSX-V:KNE (5/1/2025, 7:00:00 PM)

0.08

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-01 2025-04-01
Earnings (Next)05-22 2025-05-22
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners41.01%
Ins Owner ChangeN/A
Market Cap12.38M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 8
Fwd PE N/A
P/S 5.88
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.01
EY12.5%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS0
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 56.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 105.28%
GM 50.8%
FCFM N/A
ROA(3y)-77.63%
ROA(5y)-68.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y23.23%
GM growth 5Y36.67%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.61%
Cap/Sales 0.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.8
Quick Ratio 0.55
Altman-Z -15.23
F-Score5
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)80.71%
Cap/Depr(5y)116.53%
Cap/Sales(3y)19.54%
Cap/Sales(5y)14.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)122.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.21%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-23.34%
Revenue growth 3Y-51.93%
Revenue growth 5Y-20.25%
Sales Q2Q%78.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.03%
OCF growth 3YN/A
OCF growth 5YN/A